Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / chronic weight management | Covered with PA |
| Obstructive sleep apnea (SURMOUNT-OSA indication) | Covered with PA |
Plan type: Commercial fully insured and ACA. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
This varies by plan. Highmark covers these drugs under its commercial and ACA pharmacy policy, but a self-funded employer can carve out anti-obesity drugs. Confirm your plan includes the benefit before submitting. The pharmacy benefit manager for most Highmark commercial plans is Express Scripts. Highmark Medicare Advantage follows CMS rules, so pure obesity is not covered and a cardiovascular or sleep-apnea pathway is required.
Coverage by indication
| BMI threshold | BMI 30 or higher, or BMI 27 or higher with a comorbidity |
| Step therapy | Six months of documented dietary change and increased physical activity is required at initiation and throughout therapy. |
What the prior authorization needs:
- Baseline height, weight, and BMI documentation
- Six months of lifestyle change documented
- Prior authorization is required
- As of August 2025, prediabetes, high triglycerides, and low HDL were added as qualifying comorbidities (effective 08/06/2025)
Policy J-1388. Source: Highmark Pharmacy Policy J-1388 Anti-Obesity (Enhanced), Commercial and ACA. Official payer policy PDF (public URL confirmed, binary; J-1388 policy number and framework confirmed via the Highmark provider bulletin at providers.highmark.com). Verified June 12, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.
Effective January 28, 2025, Highmark revised its Zepbound OSA policy to require baseline AHI documentation with optimized guideline-directed care for initiation, and an AHI reduction from baseline for reauthorization.
| BMI threshold | BMI 30 or higher |
| Sleep study (AHI) | Baseline AHI documented at initiation; moderate to severe OSA is AHI 15 or higher per SURMOUNT-OSA |
What the prior authorization needs:
- OSA diagnosis documented
- Baseline AHI with optimized guideline-directed care at initiation
- Reauthorization requires a demonstrated AHI reduction from baseline
- Lifestyle changes including diet, physical activity, and sleep hygiene
Source: Highmark, Zepbound Prior Authorization Form (multi-region). Official payer PA form PDF (public URL confirmed, binary; framework confirmed via the Highmark January 2025 formulary update at providers.highmark.com). Verified June 12, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list, then have your prescriber submit it.
- Start with the Highmark prior-authorization letter template, which cites this plan's policy and the diagnosis codes a reviewer looks for. Pick the indication that matches your clinical picture.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash-pay options in the cost guide and the cheapest legitimate programs.
Frequently asked questions
Does Highmark cover Wegovy and Zepbound?
Yes. Highmark covers Wegovy and Zepbound for obesity with prior authorization on commercial and ACA plans under policy J-1388, and covers Zepbound for sleep apnea under a separate pathway. This reflects the published policy verified June 2026.
What does Highmark require to approve Wegovy and Zepbound?
For obesity / chronic weight management: The BMI requirement is BMI 30 or higher, or BMI 27 or higher with a comorbidity. Six months of documented dietary change and increased physical activity is required at initiation and throughout therapy.
Why might Highmark deny Wegovy and Zepbound even if I meet the criteria?
Highmark covers these drugs under its commercial and ACA pharmacy policy, but a self-funded employer can carve out anti-obesity drugs. Confirm your plan includes the benefit before submitting. The pharmacy benefit manager for most Highmark commercial plans is Express Scripts. Highmark Medicare Advantage follows CMS rules, so pure obesity is not covered and a cardiovascular or sleep-apnea pathway is required.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources and the row is marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit, so those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
